Development of a novel six‐long noncoding RNA signature predicting survival of patients with bladder urothelial carcinoma

Abstract

Bladder urothelial carcinoma is a malignant tumor with a high incidence in the uropoietic system. Considerable studies have shown that long noncoding RNA (lncRNA) plays an important role in the development and progression of bladder urothelial carcinoma. In this study, the lncRNA expression and clinical data of 377 bladder urothelial carcinoma patients were obtained from The Cancer Genome Atlas database and differentially expressed lncRNAs in cancer and normal groups were evaluated. Univariate COX and multivariate COX regression analyses of prognosis were performed on differentially expressed lncRNAs in the training data sets, six prognosis-related lncRNAs (LINC02195, LINC01484, LINC01468, SMC2-AS1, AC011298.1, and PTPRD-AS1) were assessed, and a six-lncRNA signature was constructed. The predictive capability of this six-lncRNA signature was validated in the testing data sets and entire data sets. The prognostic ability of the six-lncRNA signature was independent of other clinical elements after multivariate COX regression and stratified analyses of with other clinical elements. We performed functional enrichment analysis with the six prognosis-related lncRNAs. Results of functional enrichment revealed that these prognosis-related lncRNAs might promote the development and metastasis of bladder urothelial carcinoma. In summary, the six-lncRNA signature that we developed could effectively predict the prognosis of bladder urothelial carcinoma patients. This six-lncRNA signature might be a novel independent prognostic marker of bladder urothelial carcinoma. Moreover, it also provides novel insights into the mechanism of bladder urothelial carcinoma.

Identification of an immune-related long non-coding RNA signature and nomogram as prognostic target for muscle-invasive bladder cancer

“…Nowadays, many studies used high-throughput sequencing data to identify gene signatures and construct clinical predictive models. Gao et al [39] identified a 6-lncRNA signature to predict the prognosis of BCa and their AUC for 5-year survival is 0.751, which is similar to 0.742 by our signature. However, they didn't report the AUC value for 1-year survival and thus the predictive power for short-term follow-up is uncertain.…”

LNCAROD is stabilized by m6A methylation and promotes cancer progression via forming a ternary complex with HSPA1A and YBX1 in head and neck squamous cell carcinoma

“…Among those upregulated lncRNAs, lncRNA‐activating regulator of DKK1 (LNCAROD) (also named aslnc‐MBL2‐4 or LINC01468) was found to be overexpressed in HNSCC samples, which is in consistent with a previous report (Gao et al , 2014). LNCAROD is also highly expressed in bladder urothelial carcinoma and predicts unfavorable prognosis (Gao et al , 2019), suggesting an oncogenic role in cancer development. Thus, it was chosen for further validation.…”

Identification and Validation of an Individualized Prognostic Signature of Bladder Cancer Based on Seven Immune Related Genes

“…Till date, no report on IRG-based prognostic signatures exists, although considerable efforts have been made to develop prognostic signatures based on differentially expressed genes (Gao et al, 2019;Yan et al, 2019;Zhang et al, 2019). We identified seven prognostic IRGs based on a comprehensive analysis which could serve as valuable biomarkers in the clinical setting.…”